49 results about "Renal Failures" patented technology

The invention provides application of enhanced mesenchymal stem cells and exosomes in chronic nephritis and renal failure, and belongs to the technical field of biological medicine manufacturing. Through composite pretreatment of salidroside and astragalus polysaccharide, the treatment potential of exosomes secreted by the mesenchymal stem cells is remarkably enhanced, a new thought is provided for intervention of the chronic kidney diseases, and various pathologies of the chronic kidney diseases are covered. In addition, a 3D microenvironment constructed by fibrin gel is combined to simulate an in-vivo extracellular matrix, the natural growth state of the stem cells is better fitted, directional differentiation and function regulation of the stem cells are promoted, and therefore the biological activity and targeting performance of the exosome are improved.

The utility model provides a bioreactor device for replacing the function of a renal tubule, the bioreactor device is placed in a cell culture incubator, the bioreactor device comprises a fixed frame and a chip, the chip is arranged on the fixed frame, and a vein-imitated renal tubule structure is formed in the chip; openings in the two ends of the flow channel are respectively a liquid inlet and a liquid outlet; the inner diameter of the main flow channel is larger than that of the micro flow channel; wherein the inner diameter of the main flow channel and the inner diameter of the micro flow channel of the chip are both within the pipe diameter range of the physiological renal tubule; a human renal tubular epithelial cell suspension enters the vein-imitating flow channel from the liquid inlet and is attached to the inner wall of the vein-imitating flow channel. Therefore, the structure of the renal tubule is reflected in a more bionic and more reasonable manner, the physiological environment of the renal tubule can be simulated more accurately, a new design thought and method are provided for a renal tubule bioreactor device in a bioartificial kidney, the difficulty in the field of kidney replacement therapy is expected to be solved, and the life quality of patients with end-stage renal failure due to nephropathy is improved.

To provide a composition for preventing, ameliorating or treating a disease caused by protein nitration comprising a peptide with terminal tyrosine as an effective component.SOLUTION: A peptide with terminal tyrosine has an excellent effect of inhibiting protein nitration and also an excellent effect of preventing, ameliorating or treating disease symptoms in chronic immobilization stress-induced depression / cognitive impairment model, Alzheimer's disease model, epileptic seizure model, stroke model, type 2 diabetes model, acute renal failure model, or hyperammonemia model.SELECTED DRAWING: None

This invention belongs to the field of pharmaceutical analysis, specifically relating to a method for constructing a fingerprint spectrum of Shenfushu granules. The method for constructing a fingerprint spectrum of Shenfushu granules provided by this invention features high accuracy, high stability, good repeatability, good specificity, and strong specificity. The fingerprint spectrum analysis method for Shenfushu granules, a traditional Chinese medicine preparation for treating chronic renal failure, established by this invention can not only qualitatively analyze and identify the seven chemical components contained in this preparation, but also simultaneously present the characteristic peaks of five traditional Chinese medicines in the prescription, achieving the goal of overall quality control of multiple medicinal ingredients.

The application discloses a Bifidobacterium longum subsp.longum strain for relieving pathological characteristics of mice with chronic kidney disease induced by adenine, and belongs to the technical fields of microorganisms and medicines.The application provides a biomarker combination related to end-stage renal disease of peritoneal dialysis, wherein the corresponding species abundance in the biomarker combination presents significant difference in matched healthy control population and peritoneal dialysis population, can effectively distinguish the end-stage renal disease population of peritoneal dialysis and the healthy population, and has high sensitivity and specificity.The application also provides a Bifidobacterium longum subsp.longum strain CCFM1375 capable of delaying the progression of renal failure, which can be used for preparing products for improving chronic kidney disease.

The present invention relates to an artificial intelligence model and an implementation method therefor, which are capable of selecting and extracting, from CT images of patients with IgA nephropathy, image features significant for prognostic prediction and applying same to a machine learning model to thereby predict, with high accuracy, the likelihood of the patients with IgA nephropathy progressing to end-stage renal failure within five years. The present invention provides a prognostic prediction model that rapidly predicts the prognosis of a patient without an invasive kidney biopsy, overcomes the limitations of conventional pathology diagnosis relying on invasive methods, and enables periodic prognostic evaluation with significantly improved reliability. In addition, the present invention is capable of precisely reflecting characteristics of each item and accurately predicting a clinical course of a patient, by combining various feature selection methods and binary classifiers for each item of mesangial hypercellularity (M), endothelial hypercellularity (E), segmental glomerulosclerosis (S), and tubular atrophy / interstitial fibrosis (T), which constitute a MEST score.

A medical device system includes renal failure therapy machines each including a memory. The renal failure therapy machines are communicatively coupled such that the memories collectively form a distributed database. The system also includes a logic implementer associated with each renal failure therapy machine. Each logic implementer is programmed to automatically access the distributed database, so that each renal failure therapy machine periodically delivers prescription input parameters and / or treatment output data to at least one of the other renal failure therapy machines, and retrieves prescription input parameters and / or treatment output data from at least one of the other renal failure therapy machines. One of the renal failure therapy machines is configured to create at least one treatment record trend from the treatment output data and to share the at least one treatment record trend with other renal failure therapy machines through the distributed database.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using as says that detect Chitinase-3-like protein 1 as diagnostic and prognostic biomarker assays in renal injuries.

An extracorporeal and drug delivery system includes (i) a renal failure therapy machine operable with a blood filter in fluid communication with an arterial line and a venous line, the machine including (a) an effluent pump for pumping effluent from the blood filter at an effluent flowrate, and at least one of (b) a dialysis fluid pump for pumping dialysis fluid to the blood filter at a dialysis fluid flowrate, (c) a predilution pump for pumping replacement fluid into the arterial line at a predilution flowrate, or (d) a postdilution pump for pumping replacement fluid into the venous line at a postdilution flowrate; (ii) an infusion pump operable to deliver an intravenous (“IV”) drug to the patient at an IV drug flowrate; and (iii) a coordinating logic implementor configured to adjust the IV drug flowrate based on an amount of the IV drug removed via the effluent flowrate.

A renal failure therapy system includes a fresh dialysis fluid tube having a connector for connecting to a dialyzer, a spent dialysis fluid tube having a connector for connecting to the dialyzer, a dialysis fluid circuit including a fresh dialysis fluid line, a spent dialysis fluid line, at least one of (i) a first disinfection device positioned between the fresh dialysis fluid line and the fresh dialysis fluid tube, or (ii) a second disinfection device positioned between the spent dialysis fluid line and the spent dialysis fluid tube, and recirculation circuitry extending to a first machine connector for mating with the connector of the fresh dialysis fluid tube during disinfection and a second machine connector for mating with the connector of the spent dialysis fluid tube during disinfection. The system also includes a control unit configured to cause the first and second disinfection devices to be energized during the local disinfection.

The invention provides a peritoneal dialysis device for renal failure, and belongs to the technical field of peritoneal dialysis. Comprising a positioning disc, an in-vivo dialysis tube, an in-vitro dialysis tube and a buffering assembly, the in-vivo dialysis tube and the in-vitro dialysis tube are installed on the positioning disc, the buffering assembly is used for buffering traction force on the in-vitro dialysis tube, the buffering assembly is further used for supporting and positioning the in-vivo dialysis tube, and the buffering assembly is connected with the positioning disc and a positioning plate. By arranging the buffer assembly, the in-vivo dialysis tube can be plastically fixed, the phenomenon that the in-vivo dialysis tube deviates and floats upwards after being used in the body of a patient for a long time is prevented, the difficulty of peritoneal dialysis operation of the patient is reduced, redundant in-vitro dialysis tubes outside the body of the patient can be stored, and the in-vivo dialysis tube fixing device is convenient to use. When the extracorporeal dialysis tube is pulled, the buffering assembly can absorb and buffer the pulling force at the first time, the situation that the pulling force directly acts on the skin of a patient, and consequently the patient feels uncomfortable is avoided, and the safety of the peritoneal dialysis device in daily use is improved.

A platform for patient engagement and treatment compliance is disclosed. In an example, a system includes a home therapy machine configured to perform a renal failure therapy treatment. The system also includes a mobile communication device including an application that enables a patient to select a program type for a future renal failure therapy treatment. The application is configured to determine a short program and a long program are available for the future renal failure therapy treatment and cause a user interface to provide an option to select one of the short program or the long program. The application is also configured to receive a selection of the short program or the long program via the user interface and transmit a message to the home therapy machine, the message indicative of the selection of the short program or the long program for the future renal failure therapy treatment.

The invention belongs to the technical field of biological medicines, and particularly discloses a liposome containing a natural extract composition as well as a preparation method and application of the liposome. The method for preparing the liposome containing the natural extract composition comprises the following steps: S1, adding the grape, poria cocos and apple extract, cholesterol and lecithin into an organic solvent, heating, stirring and dissolving to obtain an organic phase; adding the soybean extract and the ginseng extract into ultrapure water, heating and stirring to obtain a water phase; and S2, slowly adding the organic phase into the water phase while stirring, continuing stirring and emulsifying, and removing the organic solvent by reduced pressure distillation to obtain a liposome suspension. And S3, filtering the suspension, adding a freeze-drying protective additive, and freeze-drying to obtain the liposome. The invention also covers the application of the liposome in treating renal failure. In the invention, through the combination of natural extracts and the combination of a specific composition and liposome administration, the components generate a synergistic effect, and the pharmaceutical composition has a remarkable treatment effect on renal failure, especially chronic renal failure.

An object of the present invention is to improve the treatment and / or prevention of cardiovascular and renal diseases compared to already known monotherapies. A further object of the present invention is to provide a combination of pharmaceutical active ingredients for treating cardiovascular diseases, particularly cardiac and renal failure, characterized by chronic sodium retention, which reduces patient mortality and / or morbidity. Another object of the present invention is to improve the treatment and / or prevention of cardiovascular and renal diseases by administering a combination comprising finerenone and an SGLT2 inhibitor. [Solution] The present invention relates to pharmaceutical compositions and combinations comprising finerenone or its hydrate, solvate, or pharmaceutically acceptable salt or polymorph thereof, and an SGLT2 inhibitor or its hydrate, solvate, or pharmaceutically acceptable salt or polymorph thereof. The combinations can be used for the treatment and / or prevention of cardiovascular and / or renal diseases in humans and other mammals.

An extracorporeal and drug delivery system includes a renal failure therapy machine operable with a blood filter in fluid communication with an arterial line and a venous line, the machine including an effluent pump for pumping effluent from the blood filter, and at least one of a dialysis fluid pump for pumping dialysis fluid to the blood filter at a dialysis fluid flowrate, a predilution pump for pumping replacement fluid into the arterial line at a predilution flowrate, or a postdilution pump for pumping replacement fluid into the venous line at a postdilution flowrate; an infusion pump operable to deliver an intravenous (“IV”) drug to the patient; and a coordinating logic implementor configured to determine if a formulation adjustment should be made to the IV drug when a constituent of the IV drug exists in the dialysis fluid, the predilution replacement fluid, and / or the postdilution replacement fluid.

A renal failure blood therapy system includes a memory device storing a therapy target for a patient. The system also includes a processor configured to receive the therapy target for the patient, receive a desired solute concentration for the patient, and apply the therapy target and the desired solute concentration as inputs to an optimization routine. The processor is also configured to execute the optimization routine to determine at least one dialysis therapy prescription specifying at least a dialysis therapy duration, a dialysis therapy frequency, and at least one of a dialysis therapy blood flow rate or a dialysis therapy dialysate flow rate. The processor is further configured to display the at least one dialysis therapy prescription for confirmation or selection by a clinician and transmit the selected or confirmed dialysis therapy prescription to a dialysis machine for a subsequent dialysis treatment for the patient.

A renal failure therapy system includes a fresh dialysis fluid tube having a connector for connecting to a dialyzer, a spent dialysis fluid tube having a connector for connecting to the dialyzer, a dialysis fluid circuit including a fresh dialysis fluid line, a spent dialysis fluid line, at least one of (i) a first disinfection device positioned between the fresh dialysis fluid line and the fresh dialysis fluid tube, or (ii) a second disinfection device positioned between the spent dialysis fluid line and the spent dialysis fluid tube and recirculation circuitry extending to a first machine connector for mating with the connector of the fresh dialysis fluid tube during disinfection and a second machine connector for mating with the connector of the spent dialysis fluid tube during disinfection. The system also includes a control unit configured to cause the first and second disinfection devices to be energized during the disinfection.

The present invention provides an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment of a chronic or acute disease or acute condition in a patient to prevent or reduce organ dysfunction or organ failure. In a preferred embodiment, the invention provides an anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment of a chronic or acute disease or acute condition in a patient to prevent or reduce renal dysfunction or renal failure or hepatic dysfunction or hepatic failure.

The invention belongs to the technical field of nano-materials and biological medicines, and relates to a nano-drug delivery system based on exosome and a metal organic framework as well as a preparation method and application of the nano-drug delivery system. The exosome core, the composite metal organic framework layer and the polydopamine layer are sequentially arranged from inside to outside to form nano-particles, the surface of the polydopamine layer is modified with an antibody targeting a target organ, and the composite metal organic framework layer is formed by compounding a metal organic framework formed by zinc ions and Cu-Cys. The nano-drug delivery system provided by the invention can specifically target lungs, livers and kidneys respectively, the delivery efficiency and stability of the exosomes are improved, the controllable release of the exosomes is realized, and the anti-inflammatory, anti-oxidation, anti-fibrosis and tissue repair effects of the exosomes are better played, so that the degrees of pulmonary fibrosis, fatty liver and renal failure are reduced; the composite material has the characteristics of strong targeting property, clear structure, high specific surface area and porosity, easiness in chemical functionalization and the like.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein moiety A, R1, and R2 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia- reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism- related disease and genetic disorder of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament and methods of prevention and / or treatment of such diseases.

The present application relates to a kind of wearable arteriovenous fistula blood flow noninvasive monitoring device, which is based on the principle of fluid heat transfer, and is a wireless wearable electronic device for noninvasive measurement of arteriovenous fistula blood flow of patients undergoing maintenance hemodialysis due to renal failure, comprising a top PDMS package (1), a back-end processing module (2), a middle PDMS partition package (4), a front-end test module (5) and a bottom PDMS package (6). Compared with the prior art, the present application fully utilizes the small and portable characteristics of wearable electronics, the low sensitivity of material thermodynamic properties to motion state and the time average effect, solves the problems of low measurement accuracy, inconvenience of carrying and easy to cause treatment delay of existing blood flow measurement equipment, and reduces the risk of fistula occlusion of hemodialysis patients.

A phenothiazine ferroptosis inhibitor, a preparation method therefor and an application thereof. Specifically provided is a compound represented by formula I, or a salt thereof, or a stereoisomer thereof. The synthesized phenothiazine compound has a good inhibitory effect on ferroptosis and has good drug safety. Moreover, the compound can be used to prepare a ferroptosis inhibitor, and can also be used to prepare a drug for treating diseases related to ferroptosis, such as neurodegenerative diseases, tumors, tissue ischemia reperfusion injury, stroke, cardiovascular diseases, renal failure, and diabetic complications.

An extracorporeal and drug delivery system includes: (i) a renal failure treatment machine operable with a blood filter in fluid communication with an arterial line and a venous line, the machine including: (a) an effluent pump for pumping effluent from the blood filter at an effluent flow rate; and at least one of: (b) a dialysis fluid pump for pumping dialysis fluid to the blood filter at a dialysis fluid flow rate; (c) a pre-dilution pump for pumping replacement fluid into the arterial line at a pre-dilution flow rate; or (d) a post-dilution pump for pumping replacement fluid into the venous line at a post-dilution flow rate; (ii) an infusion pump operable to deliver an intravenous ("IV") drug to a patient at an IV drug flow rate; and (iii) a coordination logic implementer configured to adjust the IV drug flow rate based on an amount of the IV drug removed via the effluent flow rate.

The preparation method comprises the following steps: by taking traditional Chinese medicine puffball as a carbon source, carrying out iron ion complexing modification to form a metalloid organic complex material, then carrying out high-temperature calcination in an inert atmosphere to prepare the magnetic porous carbon microspheres, and then sequentially carrying out KOH and selenium powder activation treatment to obtain the selenized magnetic porous carbon microspheres for blood perfusion. And preparing the selenized magnetic porous carbon microspheres with high specific surface area, large pore capacity and hierarchical pore structure. The raw materials used in the invention are low in cost, green and environment-friendly, the preparation method is simple, the conditions are mild, and the obtained selenized magnetic porous carbon microspheres are stable in performance, have biocompatibility, self-antibiosis, uricase-like and antioxidant enzyme-like functions, and are expected to be used as a blood perfusion adsorbent for in vitro treatment of refractory acute gout kidney or renal failure.

The invention discloses a hippocampus extract with activity of improving renal anemia as well as a preparation method and application of the hippocampus extract, and belongs to the technical field of biological medicines. The hippocampus extract with different molecular magnitudes is prepared through optimization of a membrane separation process, experiments prove that the hippocampus extract can remarkably improve the activity of fluorescein enzyme and promote generation of EPO of a human embryonic kidney cell HEK293 cell line, and particularly, the blood enriching activity of the hippocampus extract with the molecular weight smaller than 20 kDa is obviously higher than that of a hippocampus total extract, so that the hippocampus extract with the molecular weight smaller than 20 kDa has a good application prospect. The traditional Chinese medicine composition can effectively reduce the inosine and urea nitrogen levels of rats suffering from renal injury type anemia and improve renal failure, and has the effect of remarkably improving renal anemia. The hippocampus extract obtained through optimization of the preparation method relieves the symptoms of renal anemia from multiple aspects, improves renal injury, provides a scientific basis for clinical research of drugs for improving renal anemia and development of functional foods, and has great application value.

The invention provides a novel ferroptosis inhibitor as well as a preparation method and application thereof, and belongs to the technical field of chemical synthesis medicines. The invention synthesizes a compound shown in the formula I and having a good inhibition effect on ferroptosis, and the compound can be used for preparing a ferroptosis inhibitor. The compound can also be used for preparing medicines for treating diseases such as ischemia-reperfusion injury, drug-induced liver injury, acute kidney injury, renal failure, hepatic pulmonary fibrosis, neurodegenerative diseases, cerebral apoplexy, myocarditis, myocardial infarction, heart failure, arthritis, chronic atrophic gastritis and the like related to ferroptosis, and has a wide market prospect.

The application provides a traditional Chinese medicine composition for treating uremia and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition for treating uremia is prepared from raw materials and is characterized by kidney-tonifying, spleen-strengthening, qi-benefiting, turbidity-removing, dampness-removing and blood-stasis-removing, and is an effective medicine for treating chronic renal failure and is worth popularization and application.

The invention discloses a method for detecting the total amount of guanidines in body fluids of patients with renal failure, comprising the following steps: S1: sample pretreatment and preparation of a test solution: S11: collecting and processing sample 1: taking 5 ml of blood from a patient with renal failure, centrifuging at 3000 r / min for 10 minutes, filtering the supernatant through a 0.45 μm filter membrane, and placing it in a 2-8°C refrigerator for standby use; S12: collecting and processing sample 2: taking 5 ml of urine and peritoneal dialysis waste fluid from a patient with renal failure, filtering the supernatant through a 0.45 μm filter membrane, and placing it in a 2-8°C refrigerator for standby use; S13: preparing a test stock solution: accurately measuring sample 1 or sample 2, 3 ml of which is placed in a 10 ml volumetric flask, diluting with water to the scale, and shaking well. The invention establishes a method for determining the total amount of guanidines in body fluids of patients with renal failure, solves the problem that the determination solution is easily discolored, and realizes the accurate detection of guanidine groups in the body fluids of patients with renal failure; the determination method is simple, easy to operate, and short in time; not only improves the detection efficiency, but also improves the quality and safety of the product.

The invention provides a traditional Chinese medicine composition for treating chronic renal failure as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating chronic renal failure is prepared from the following raw materials: rheum officinale, polygonum cuspidatum, leonurus, astragalus membranaceus, dandelion, poria cocos, plantain herb, herba lycopi, white mulberry root-bark, radix paeoniae alba and eclipta. The traditional Chinese medicine composition adjusts traditional Chinese medicine components, follows the compatibility principle of monarch, minister, assistant and guide and the structure theory, reasonably organizes medicines, enhances the curative effect, reduces toxic and side effects, comprehensively takes care of the illness state, improves the treatment effect of the traditional Chinese medicine composition on chronic renal failure, adjusts the abnormal levels of serum urea nitrogen and serum creatinine, and improves calcium and phosphorus metabolism disorder.

The application provides an application of enhanced mesenchymal stem cells and exosomes in chronic nephritis renal failure, and belongs to the technical field of biological medicine manufacturing.The application significantly enhances the treatment potential of exosomes secreted by mesenchymal stem cells through the composite pretreatment of rhodioside and astragalus polysaccharide, provides a new idea for the intervention of chronic kidney disease, and covers various pathologies of chronic kidney disease.The application also combines a 3D microenvironment simulated by a fibrin gel constructed extracellular matrix in the body, is more suitable for the natural growth state of stem cells, promotes the directional differentiation and functional regulation of stem cells, and thus improves the biological activity and targeting of the exosomes.